# Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia

> **NCT05918198** · PHASE2 · UNKNOWN · sponsor: **Peking University People's Hospital** · enrollment: 52 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Ven+CAG

## Key facts

- **NCT ID:** NCT05918198
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2023-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05918198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05918198, "Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-09-15 from https://api.ai-analytics.org/clinical/NCT05918198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*